Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Radiotherapy Plus Tislelizumab and Afatinib for Neoadjuvant Treatment of Resectable HNSCC
NCT06494189Phase 1Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tislelizumab and afatinib in head and neck squamous cell carcinoma (HNSCC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Dose-Limiting Toxicity Incidence. Started Jul 2024; status: completed.
02
Drugs
tislelizumabafatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06494189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06494189.